{"id":"W4380854067","doi":"10.1182/blood.2022019386","title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Genentech","keywords":"Medicine; Pembrolizumab; Internal medicine; Discontinuation; Cohort; Adverse effect; Brentuximab vedotin; Surgery; Salvage therapy; Chemotherapy; Lymphoma; Cancer; Immunotherapy; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000140163,0.0002468993,0.0005542455,0.0001729237,0.00008125905,0.00001619349,0.0001283814,0.0001997554,0.00009049182],"category_scores_gemma":[0.000126099,0.0002005083,0.0004013282,0.0002886622,0.00007592389,0.00006014312,0.00004079986,0.00005998708,0.0001637515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000108829,"about_ca_system_score_gemma":0.0002452284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006669227,"about_ca_topic_score_gemma":0.00001510146,"domain_scores_codex":[0.9984132,0.00004064092,0.0003794296,0.0004111727,0.0003493795,0.0004061436],"domain_scores_gemma":[0.9987543,0.0003213726,0.0001354747,0.0004971459,0.0001097301,0.0001819671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02692447,0.03734601,0.431024,0.001417027,0.008360894,0.001440246,0.005303069,0.00002314117,0.04409315,0.01330679,0.2058935,0.2248676],"study_design_scores_gemma":[0.2615455,0.007266902,0.5611618,0.0004130444,0.001629736,0.000095221,0.0003513229,0.0003037779,0.08577444,0.001018169,0.07983315,0.0006068858],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955974,0.0005301003,0.00002324225,0.0009918171,0.0003152109,0.0007863718,0.0001027358,0.0001771274,0.001476056],"genre_scores_gemma":[0.9935442,0.0004614812,0.000588774,0.0002366664,0.0002756715,0.0003132639,0.000128011,0.00006897997,0.004382954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.234621,"threshold_uncertainty_score":0.8176493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02062562091102287,"score_gpt":0.2741899358055085,"score_spread":0.2535643148944856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}